Skip to content
2000
Volume 7, Issue 9
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

New antifungals are needed in the medicine because of more aggressive and invasive diagnostic and therapeutic methods used, rapid emergence of resistant and new opportunistic fungi, increasing number of patients suffering from immunosuppressive situations e.g., AIDS, transplantation, cancer, etc. Several classes of new antifungal agents are discussed here including some new members of known families. Voriconazole, posaconazole and ravuconazole, are novel triazoles that inhibit the ergosterol synthesis. These drugs overcome problems associated with the ineffectivity of fluconazole against some Aspergillus spp. or the variable bioavailability of itraconazole. Echinocandins (caspofungin, anidulafungin and micafungin) represent a new family of antifungal agents that inhibit 1,3-β-glucan synthase. Nikkomycins targeting the chitin synthase, show activity against Histoplasma capsulatum and Blastomyces dermatitidis. Sordarin derivatives that block the fungal protein synthesis can be considered as a promising new class of antifungal agents for the treatment of Candida and Pneumocystis infections.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/138955707781662672
2007-09-01
2025-06-28
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/138955707781662672
Loading

  • Article Type:
    Research Article
Keyword(s): echinocandins; nikkomycins; posaconazole; ravuconazole; sordarins; Voriconazole
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test